<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640911</url>
  </required_header>
  <id_info>
    <org_study_id>SALT-C</org_study_id>
    <nct_id>NCT02640911</nct_id>
  </id_info>
  <brief_title>An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-centre study will evaluate the safety and related factors study of atypical&#xD;
      antipsychotics long-term treatment in Chinese Patients with Schizophrenia. The atypical&#xD;
      antipsychotics include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone,&#xD;
      paliperidone , amisulpride , perospirone and clozapine. This is an open, cohort, multi-center&#xD;
      observational clinical study. The main purpose is to evaluate the safety. And the second&#xD;
      purpose is to evaluate the efficacy of atypical antipsychotics. The efficacy evaluations&#xD;
      include symptoms, social function, recurrence rate and hospitalization. This study belongs to&#xD;
      IV period post-marketing drugs research. Planned sample size is 3000 cases.&#xD;
&#xD;
      Visits occurs at 0,4,8,13,26,52,78,104,130 and 156 weeks. The main indexes include physical&#xD;
      examination, vital signs, abdominal circumference , laboratory tests (blood cell analysis/&#xD;
      blood biochemical tests / prolactin (PRL) / thyroxine, etc.), adverse events, 12-lead&#xD;
      electrocardiogram( ECG), extrapyramidal syndrome(EPS )assessment, sexual function evaluation,&#xD;
      medication and other subjective feelings. The second indexes include scales of Positive and&#xD;
      Negative Syndrome Scale(PANSS)，Clinical Global Impression-severity of Illness Scale(CGI-S),&#xD;
      Calgary Depression Scale for Schizophrenia(CDSS),Personal and Social Performance Scale(PSP),&#xD;
      the MOS 36一item Short Form Health Survey(SF-36), relapse rate, drug consolidation,&#xD;
      medical-related expenses, income, drug plasma concentration and genetic information.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">May 2033</completion_date>
  <primary_completion_date type="Anticipated">May 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Systolic Blood Pressure</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>Measure blood pressure at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline liver function</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>Measure blood biochemical tests at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline PRL</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>Measure PRL level at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline thyroxine</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>thyroxine laboratory tests at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with EPS</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>EPS assessment at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal ECG</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>ECG examination at 156 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal sexual function</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>sexual function evaluation medication at 156 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline deduction of PANSS</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>PANSS assessment at 156 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline deduction of CGI-S</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>CGI-S assessment at 156 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline deduction of CDSS</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>CDSS assessment at 156 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline deduction of PSP</measure>
    <time_frame>at 156 weeks</time_frame>
    <description>PSP assessment at 156 weeks</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Schizophrenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese Patients with Schizophrenia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. An in-patient or out-patient (male or female) and aged ≥18 years&#xD;
&#xD;
          2. A diagnosis of schizophrenia,DSM-IV(Diagnostic and Statistical Manual Diploma in&#xD;
             Social Medicine-IV)&#xD;
&#xD;
          3. Subjects must have the ability to effectively communicate with investigator,complete&#xD;
             study related documents, comprehend the key components of the consent form and must&#xD;
             provide written informed consent to participate in the study prior to any study&#xD;
             specific assessments or procedures.&#xD;
&#xD;
          4. Patients are taking or will take atypical antipsychotics which include quetiapine,&#xD;
             olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone , amisulpride ,&#xD;
             perospirone and clozapine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in other clinical studies.&#xD;
&#xD;
          2. Other conditions which, in the investigator's judgment, render patients unsuitable for&#xD;
             the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huafang Li, PH.D</last_name>
    <phone>86-21-34773128</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang Li, PH.D</last_name>
      <phone>86-2134773128</phone>
      <email>lhlh_5@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

